Overview

Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The study aims to evaluate the safety and preliminary efficacy of the combination of cabozantinib and pembrolizumab in advanced melanoma
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Yousef Zakharia
Collaborators:
Exelixis
University of Iowa
Treatments:
Pembrolizumab